Transaction · 0001649094-25-000014

GUGGENHIME ANDREW

GUGGENHIME ANDREW, PRES, reported an open-market or private sale at Vaxcyte, Inc. involving 6182.000000 shares for an estimated $517056.30. Reported holdings after the transaction were 111309.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SPRES
PCVXVaxcyte, Inc.
Filing timeFeb 19
Trade dateFeb 18, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
…
Pre-filing
…
Returns since
…

PCVX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
PCVX since 2025-02-19Filed 561 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001649094-25-000014
Common Stock
Transaction date
Feb 18, 2025
Filed Feb 19, 2025, 11:04 PM · 1d delay
Shares
6.18k sh
$8.36k per share
Estimated value
-$51.7M
Computed from shares × price
Holdings after
111k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Direct Ownership Large Sale Repeat Seller 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

PRESIDENT AND CFO

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted May 17, 2024.

  2. F2

    The price reported is a weighted-average price. The shares were sold at prices ranging from $83.17 to $84.10. The reporting person will provide upon request to the SEC, the issuer or security holder o…

  3. (2 footnotes)

    issuer, full information regarding the number of shares sold at each separate price.

  4. F3

    The price reported is a weighted-average price. The shares were sold at prices ranging from $84.125 to $84.985. The reporting person will provide upon request to the SEC, the issuer or security holder…

  5. F4

    Option is fully vested and exercisable

Original filing · 0001649094-25-000014
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

PCVX